Bristol Myers Squibb (NYSE: BMY) reported first quarter 2024 earnings results today. Total revenues increased 5% year-over-year to $11.9 billion. When adjusted
Key highlights from Bristol Myers Squibb’s (BMY) Q1 2024 earnings results
Categories
pharmaceuticals
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided
BIIB Earnings: Biogen Q1 2024 adj. earnings rise despite lower revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Wednesday reported an increase in adjusted profit for the first quarter of 2024, despite a decline
Earnings: Trxade Health (MEDS) reports lower revenues for fiscal 2023
Trxade Health, Inc. (NASDAQ: MEDS), a leading health service IT company, reported a decline in revenues for fiscal 2023. The company’s full-year
ISRG Earnings: Intuitive Surgical reports higher Q1 revenue and profit
Medical device company Intuitive Surgical, Inc. (NASDAQ: ISRG) announced operating results for the first quarter of 2024, reporting higher revenues and adjusted
Key takeaways from Johnson & Johnson’s (JNJ) Q1 2024 earnings report
Over the years, Johnson & Johnson (NYSE: JNJ) has constantly ramped up its portfolio and pipeline. After spinning off the consumer health
JNJ Earnings: Key quarterly highlights from Johnson & Johnson’s Q1 2024 financial results
Johnson & Johnson (NYSE: JNJ) reported first quarter 2024 earnings results today. Reported sales increased 2.3% year-over-year to $21.4 billion. The company
PACS Group gears up for $400 million IPO. Here’s all you need to know
After a slow start to the year, the IPO market is witnessing a rush of tech and healthcare companies seeking to go
ANGO Earnings: Highlights of AngioDynamics’ Q3 2024 results
AngioDynamics Inc. (NASDAQ: ANGO) has reported a wider net loss for the third quarter of 2024 when the medical device maker's revenue
Femasys is committed to providing women with revolutionary healthcare products: CEO
Femasys Inc. (NASDAQ: FEMY) is a healthcare company that develops women's reproductive health solutions using state-of-the-art technology. The company’s portfolio includes minimally
WBA Earnings: Walgreens Boots Alliance Q2 profit and sales beat estimates
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Thursday reported stronger-than-expected earnings and revenues for the second quarter of 2024. Net profit, on
IPO Alert: What to look for when Boundless Bio goes public
Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of
LatAm healthcare firm Auna prepares for NYSE listing; to raise $420 million in IPO
IPO activity gathered momentum this year in a sign that the market is recovering from the weakness experienced in 2023. The resilience
Earnings Summary: CooperCompanies (COO) reports strong Q1 2024 results
Medical device maker CooperCompanies (NYSE: COO) announced financial results for the first quarter of 2024, reporting an increase in revenues and adjusted
Earnings Summary: Dentsply Sirona reports higher sales for Q4 2023
Dentsply Sirona Inc. (NASDAQ: XRAY), a leading manufacturer of professional dental products and technologies, reported fourth-quarter 2023 financial results, reporting an increase
Earnings: Agilent’s (A) Q1 2024 profit declines on lower revenues
Healthcare company Agilent Technologies Inc. (NYSE: A) reported a decrease in adjusted earnings for the first quarter of 2024 when its revenues
Infographic: Highlights of Moderna’s (MRNA) Q4 2023 earnings results
Biotechnology company Moderna, Inc. (NASDAQ: MRNA) reported a sharp decline in revenues and earnings for the fourth quarter of 2023. Net income
Earnings Summary: Organon reports financial results for Q4 2023
Pharmaceutical company Organon & Co. (NYSE: OGN) has reported higher revenues and adjusted earnings for the fourth quarter of 2023. Total revenue
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biotechnology company that works with leading researchers and institutions to accelerate the development of new
BIIB Earnings: Here’s everything you need to know about Biogen’s Q4 report
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the fourth quarter of 2023. Total
Earnings Summary: Catalent (CTLT) slips to a loss in Q2; revenue down 10%
Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, on Friday reported a net loss